MiR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer

Cell Death and Disease

Volumn 3, Issue 11, 2012, Pages

  Sacconi, A ^a   Biagioni, F ^a   Canu, V ^a   Mori, F ^a   Di Benedetto, A ^a   Lorenzon, L ^b   Ercolani, C ^a   Di Agostino, S ^a   Cambria, A M ^c   Germoni, S ^a   Grasso, G ^c   Blandino, R ^d   Panebianco, V ^d   Ziparo, V ^b   Federici, O ^a   Muti, P ^e   Strano, S ^a   Carboni, F ^a   Mottolese, M ^a   Diodoro, M ^a   Pescarmona, E ^a   Garofalo, A ^a   Blandino, G ^a   more..

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Department of Oncology   (Italy)

^d S Vincenzo Hospital   (Italy)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Bcl 2; microRNA expression profile; Prognostic value

Indexed keywords

FLUOROURACIL; MESSENGER RNA; MICRORNA; MICRORNA 204; OXALIPLATIN; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL MIGRATION; COLONY FORMING CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; STAINING; STOMACH CANCER; TUMOR ENGRAFTMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MICRORNAS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84870551976     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.160     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. Yonsei Med J 2012; 53: 248-257.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
4. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
5. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
6. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070.
7. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F et al. MicroRNA-128- 2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012; 19: 1038-1048.
8. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689.
9. Liu Z, Sall A, Yang D. MicroRNA: an emerging therapeutic target and intervention tool. Int J Mol Sci 2008; 9: 978-999.
10. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27: 1788-1793.
11. Lam EK, Wang X, Shin VY, Zhang S, Morrison H, Sun J et al. A microRNA contribution to aberrant Ras activation in gastric cancer. Am J Transl Res 2011; 3: 209-218.
12. Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011; 4: 79.
13. Oberwinkler J. TRPM3, a biophysical enigma? Biochem Soc Trans 2007; 35(Part 1): 89-90.
14. Jiao YF, Sugai T, Habano W, Uesugi N, Takagane A, Nakamura S. Clinicopathological significance of loss of heterozygosity in intestinal- and solid-type gastric carcinomas: a comprehensive study using the crypt isolation technique. Mod Pathol 2006; 19: 548-555.
15. Staub E, Grone J, Mennerich D, Ropcke S, Klamann I, Hinzmann B et al. A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer 2006; 5: 37.
16. Balachandar V, Lakshman Kumar B, Sasikala K, Manikantan P, Sangeetha R, Mohana Devi S. Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer patients. J Zhejiang Univ Sci B 2007; 8: 638-646.
17. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
18. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou AG. DIANAmirPath: integrating human and mouse microRNAs in pathways. Bioinformatics 2009; 25: 1991-1993.
19. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011; 44: 839-847.
20. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010; 11: 136-146.
21. Belka C, Budach W. Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology. Int J Radiat Biol 2002; 78: 643-658.
22. Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012; 69: 723-731.
23. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012; 29: 384-391.
24. Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010; 127: 2520-2529.
25. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372-379.
26. Yawata A, Adachi M, Okuda H, Naishiro Y, Takamura T, Hareyama M et al. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. Oncogene 1998; 16: 2681-2686.
27. Liu X, Cai H, Huang H, Long Z, Shi Y, Wang Y. The prognostic significance of apoptosisrelated biological markers in Chinese gastric cancer patients. PLoS One 2011; 6: e29670.
28. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102: 1174-1179.